MedPath

Metformin

Generic Name
Metformin
Brand Names
Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
Drug Type
Small Molecule
Chemical Formula
C4H11N5
CAS Number
657-24-9
Unique Ingredient Identifier
9100L32L2N
Background

Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.

Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.

Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.

Indication

Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)

The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.

Metformin combination products

Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
Associated Therapies
-
Clinical Trials
Related News
sciencedirect.com
·

Emerging biomarkers and molecular targets for precision medicine in cervical cancer

Cervical cancer, a major global health issue, benefits from precision medicine through biomarkers and molecular targets for early detection and personalized treatment. Advances in genomic and proteomic technologies enhance understanding and treatment strategies, aiming to improve patient outcomes and reduce disease burden.
pmc.ncbi.nlm.nih.gov
·

Potentials and future perspectives of multi-target drugs in cancer

Cancer, with over 19.3 million new cases in 2020, is a major global health issue. Traditional treatments like chemotherapy face challenges like drug resistance. Multi-target therapies, targeting multiple pathways, offer advantages such as overcoming resistance and reducing side effects. Recent advances focus on developing multi-target drugs, with several undergoing clinical trials, highlighting their potential in improving cancer treatment outcomes.
scienceofbiogenetics.com
·

How Genetics Influence Obesity and What You Can Do About It

Genetics significantly influence obesity by affecting metabolism, appetite regulation, and fat storage. Specific genes like FTO and MC4R are linked to obesity risk. However, lifestyle choices such as diet and exercise are crucial in managing weight, even for those with a genetic predisposition.
pmc.ncbi.nlm.nih.gov
·

Study Protocol of the LAUNCH 3 Trial

A randomized controlled trial compares laparoscopic and abdominal radical hysterectomy for stages IB3 and IIA2 cervical cancer, focusing on 5-year overall survival, progression-free survival, and quality of life. The study aims to provide evidence-based guidance on surgical method choice, emphasizing stringent surgical standards and oncologic principles.

Related Clinical Trials:

Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IB3,IIA2)
sph.hku.hk
·

HKUMed finds metformin could promote healthy ageing

HKUMed research using UK Biobank data suggests metformin, beyond treating diabetes, may promote healthy ageing by affecting biomarkers like phenotypic age and leukocyte telomere length. Genetic evidence supports further clinical research into metformin's repurposing for longevity, highlighting its affordability and safety.
frontiersin.org
·

Mass spectrometry-based metabolomics for discovering the bridge between traditional Chinese medicine and modern medicine

Metabolomics bridges traditional Chinese medicine (TCM) and modern medicine, enhancing TCM's scientific validation and application in diseases like cancer and cardiovascular conditions. Mass spectrometry (MS) plays a crucial role in metabolomics, offering detailed analysis of metabolites for TCM research. Despite advancements, challenges like metabolite complexity and data processing remain. Future directions include improving MS technology and integrating multi-omics for comprehensive TCM understanding.
businessinsider.com
·

People are taking a 20-cent 'wonder drug' to slow aging and lose weight. Some doctors say it's promising.

Metformin, a low-cost diabetes drug, aids weight loss and may slow aging, preventing cancers and dementia. Research suggests it mimics fasting benefits, promoting autophagy and metabolism changes. Despite potential side effects, its anti-aging and antiviral properties are under study, with a major trial, TAME, aiming to explore its impact on aging-related diseases.
finance.yahoo.com
·

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript

Editas Medicine reported Q4 2022 earnings, highlighting clinical progress with EDIT-301 for sickle cell disease and beta thalassemia, strategic shifts towards in-vivo gene editing, and financial stability extending into 2025. The company aims to advance its gene editing technologies and clinical trials, focusing on delivering transformative medicines.
pmc.ncbi.nlm.nih.gov
·

15. Management of Diabetes in Pregnancy: Standards of Care

The ADA's Standards of Care in Diabetes emphasize the importance of preconception care for individuals with diabetes planning pregnancy, aiming for glycemic control (A1C <6.5%) to reduce risks of congenital anomalies and other complications. It recommends comprehensive care, including medical nutrition therapy, regular monitoring, and avoiding harmful medications. Continuous glucose monitoring and tailored nutrition are advised to manage diabetes during pregnancy effectively.
pmc.ncbi.nlm.nih.gov
·

Integrated Bioinformatics-Based Subtractive Genomics for Identifying Novel Drug Targets Against Brucella Suis

The study employs subtractive proteo-genomics to identify novel drug targets against *Brucella suis*, a causative agent of brucellosis. It identifies 503 proteins in unique metabolic pathways, narrowing down to 114 potential drug targets. Isocitrate lyase emerges as a promising target, with six ZINC compounds showing potential inhibition. ADMET profiling recommends ZINC95543764 for further experimental studies, highlighting its potential as a therapeutic agent against brucellosis.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy